Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 6

HDL disfonksiyonunun temelindeki lipoprotein(a)’nın apolipoprotein A-I’e agregasyonu majör bir koroner risk faktörüdür

Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor

Pages
543–551
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This process is independent of ATPIII-defined MetS and exhibits risk magnitude similar to that of conventional risk factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Dysfunction of high-density lipoprotein (HDL) may contribute to coronary heart disease (CHD) risk.
📊
Key Findings & Data:Methods: A representative sample of 1509 middle-aged Turkish adults was studied at 4.9-years’ follow-up yielding 198 incident CHD cases.
💡
Conclusion & Impact:This process is independent of ATPIII-defined MetS and exhibits risk magnitude similar to that of conventional risk factors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Dysfunction of high-density lipoprotein (HDL) may contribute to coronary heart disease (CHD) risk. We determined whether aggrega- tion to lipoprotein (Lp)(a) of apolipoprotein (apo) A-I underlies HDL dysfunction conferring incident CHD risk. Methods: A representative sample of 1509 middle-aged Turkish adults was studied at 4.9-years’ follow-up yielding 198 incident CHD cases. Statistical analysis was performed using multiple linear regression and Cox proportional regression analyses. Results: In women, not age or apoA-I, rather complement C3, apoE levels and statin use were linearly related to log-Lp(a). Individuals in the low Lp(a) tertile (4.5 mg/dL) and/or triglycerides (>2.0 mmol/L). Levels actually represent aggregation of Lp(a) to apoA-I in an immune complex, rendering apoA-I atherogenic. Lp(a) did not, but apoA-I did significantly predict incident CHD (HR 1.21 [95%CI 1.07; 1.37]) in Cox regression analyses after adjustment for conventional risk factors and statin use. This adverse action of apoA-I was indepen- dent of prevalent metabolic syndrome (MetS), existed in individuals in whom ATPIII-defined MetS was not identified, and was similar in mag- nitude to that of conventional risk factors. Conclusion: Beyond being atherogenic, Lp(a) may aggregate in a pro-inflammatory milieu to apoA-I, rendering apoA-I atherogenic. This process is independent of ATPIII-defined MetS and exhibits risk magnitude similar to that of conventional risk factors.

Özet

Amaç: Yüksek yoğunluklu lipoprotein (HDL) disfonksiyonu koroner kalp hastalığına (KKH) katkıda bulunabilir. Yeni gelişen KKH riskine yük bindiren HDL disfonksiyonunun altında lipoprotein [Lp](a)’nın apolipoprotein (apo) A-I’e agregasyonunun yatabileceği keyfiyetini araştırdık. Yöntemler: Orta yaşlı Türk yetişkinlerini temsil eden 1509 kişi, 198 yeni KKH’nın geliştiği 4.9 yıllık takipte incelendi. İstatistiksel analiz çoklu reg- resyon ve Cox orantısal regresyon analizleri ile yapıldı. Bulgular: Kadınlarda, yaş veya apoA-I değil, kompleman C3 ile apoE düzeyleri ve statin kullanımının log-Lp(a) ile doğrusal ilişkisi vardı. Lp(a) alt üçte bir dilimindeki (4.5 mg/dL) ve/veya trigliserid’li (>2.0 mmol/L) koşullarda Lp(a)’nın beklenmeyen düşüşünü işaret etmekteydi. Düzeyler aslında Lp(a)’nın apoA-I ile bileşmesinden oluşan ve apoA-I’i aterojen kılan bir immün kompleksi simgeliyordu. Cox regresyonu analizinde, geleneksel risk faktörleri ve statin kullanımı için ayarlandıktan sonra, yeni gelişen KKH’yı, Lp(a) değil, apoA-I anlamlı olarak öngördü (HR 1,21 [%95 CI 1,07; 1.37]). ApoA-I’in bu olumsuz etkisi metabolik sendrom (MetS) varlığından bağımsız olup ATPIII-tanımlı MetS belirlenmemiş bireylerde de göz- lemlendi ve etki konvansiyonel risk faktörlerinin boyutuna benzerlik gösterdi. Sonuç: Lp(a), aterojen olma ötesinde, artmış yangı ortamında apoA-I’e onu aterojen kılacak biçimde agregasyon yapabilir. Bu süreç, ATPIII- tanımlı MetS’den bağımsız olup sergilediği riskin boyutu konvansiyonel risk faktörlerininkine benzerdir.

🔖

Cite This Article

CAN, G., MURAT, S., ÇİÇEK, G., ONAT, A., ÖRNEK, E., YÜKSEL, H. (2022). HDL disfonksiyonunun temelindeki lipoprotein(a)’nın apolipoprotein A-I’e agregasyonu majör bir koroner risk faktörüdür. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 6, 543–551. https://ajindex.com/articles/436315

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Onat A, Hergenç G, Bulur S, Uğur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010
  2. [CrossRef] 2. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009
  3. [CrossRef] 3. Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011
  4. [CrossRef] 4. Onat A, Kömürcü-Bayrak E, Can G, Küçükdurmaz Z, Hergenç G, Erginel-Ünaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apo E genotype and apolipoprotein B levels. Nutrition 2010
  5. [CrossRef] 5. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004
  6. [CrossRef] 6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 2009
  7. [CrossRef] 7. Onat A, Hergenç G, Özhan H, Kaya Z, Bulur S, Ayhan E, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008
  8. [CrossRef] 8. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008
  9. [CrossRef] 9. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease.: large-scale prospective data. Arch Intern Med 2008
  10. [CrossRef] 10. Werba JP Safa O, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G.Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 1993
  11. [CrossRef] 11. Tsimikas S, Brilakis ES, Miller ER, McConnell JP Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005
  12. [CrossRef] 12. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. European Atherosclerosis Socie